Rockwell Medical (FRA:RWM) Total Long-Term Assets: €17.72 Mil (As of Mar. 2026)


FRA:RWM Rockwell Medical Inc FRA:RWM
30 GF Score
Price €5.25
GF Value €0.90
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Rockwell Medical Total Long-Term Assets?

Rockwell Medical FRA:RWM 30 Total Long-Term Assets is €17.72 Mil as of Mar. 2026. GuruFocus rates FRA:RWM with a GF Score™ of 30/100 and a GF Value™ of €0.90 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. Rockwell Medical's Total Long-Term Assets for the quarter that ended in Mar. 2026 was €17.72 Mil.

Rockwell Medical Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for Rockwell Medical's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rockwell Medical Total Long-Term Assets Chart

Rockwell Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.76 10.69 21.46 21.18 16.21

Rockwell Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.36 18.22 17.02 16.21 17.72
FRA:RWM
30GF Score
Rockwell Medical Inc FRA:RWM
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rockwell Medical Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of €17.72 Mil mean?
Rockwell Medical (FRA:RWM) has a Total Long-Term Assets of €17.72 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Rockwell Medical and its competitors.
Is Rockwell Medical's Total Long-Term Assets too high?
Rockwell Medical's current Total Long-Term Assets is €17.72 Mil. Overall, Rockwell Medical has a GF Score™ of 30/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Rockwell Medical's Total Long-Term Assets compare to CPHI and TXMD?
Rockwell Medical's Total Long-Term Assets of €17.72 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on Rockwell Medical and its competitors. Rockwell Medical's current Total Long-Term Assets is €17.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rockwell Medical stock overvalued right now?
Based on GuruFocus' analysis, Rockwell Medical (FRA:RWM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.90, compared to a current price of €5.25 — trading 483.3% above its estimated fair value. The current Total Long-Term Assets is €17.72 Mil. Rockwell Medical's overall GF Score™ is 30/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For Rockwell Medical (FRA:RWM), the current Total Long-Term Assets is €17.72 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rockwell Medical (FRA:RWM) Overvalued in 2026?

Based on GuruFocus' analysis, Rockwell Medical stock appears to be overvalued. The current stock price of €5.25 is trading 483.3% above its estimated GF Value™ of €0.90. GuruFocus considers Rockwell Medical to be Significantly Overvalued.

Key valuation signals for FRA:RWM:

  • Total Long-Term Assets: €17.72 Mil
  • GF Value™: €0.90 vs. price of €5.25 (483.3% above fair value)
  • GF Score™: 30/100 with 3 warning signs

No single metric tells the full story. See the FRA:RWM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rockwell Medical Business Description

Other Exchanges RMTI:USA
Address 30142 South Wixom Road, Wixom, MI, USA, 48393
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
30GF Score

Get the complete analysis for FRA:RWM

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€0.90
GF Value